| Measure (unit/range) | Baseline (n = 84) | 12 months (n = 78) | p Value* |
| ESR (mm/1st h) | 15.0 (8.5–22.0) | 12.5 (7.0–18.3) | 0.06 |
| CRP (mg/l) | 5.0 (2.0–9.8) | 3.5 (2.0–7.0) | 0.21 |
| 28-Swollen joint count | 7.0 (3.0–10.0) | 4.0 (0.0–7.0) | <0.001 |
| 28-Tender joint count | 5.0 (1.0–11.0) | 3.0 (0.0–8.0) | 0.03 |
| MHAQ (1–4) | 1.1 (1.0–1.6) | 1.1 (1.0–1.5) | 0.65 |
| DAS28 (1–10) | 4.2 (3.0–5.1) | 3.7 (2.3–5.0) | 0.001 |
| AIMS2 (1–10) | 1.5 (0.5–3.0) | 1.0 (0.0–2.6) | 0.11 |
| Grip strength dominant hand (kg) | 20.0 (15.0–30.0) | 24.0 (16.0–33.0) | 0.02 |
| RF IgA status (% positive) | 34.1 | 24.7 | |
| RF IgM status (% positive) | 43.9 | 39.2 | |
| Anti-CCP status (% positive) | 54.8 | 52.0 |
Results are shown as median (IQR) for continuous variables and percentages for counts.
*Wilcoxon signed ranks test.
AIMS2, Arthritis Impact Measurement Scale 2; anti-CCP, anti-cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, Disease Activity Score; ESR, erythrocyte sedimentation rate; MHAQ, modified Health Assessment Questionnaire; RF, rheumatoid factor.